Replies to post #221506 on Biotech Values

[DewDiligence]

TMB seems to have some problems as a biomarker, based on the new data contained in BMY’s just-released PR (#msg-144341493).

[DewDiligence]

BMY -5% on TMB mess—and 3-month delay in FDA review—as laid out Friday’s evening’s PR (#msg-144341493).